WealthTrust Asset Management LLC Sells 18 Shares of Eli Lilly and Company (NYSE:LLY)

WealthTrust Asset Management LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,026 shares of the company’s stock after selling 18 shares during the quarter. Eli Lilly and Company accounts for 2.0% of WealthTrust Asset Management LLC’s investment portfolio, making the stock its 14th largest holding. WealthTrust Asset Management LLC’s holdings in Eli Lilly and Company were worth $2,739,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Swedbank AB bought a new stake in Eli Lilly and Company during the first quarter worth $932,797,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares during the last quarter. Wulff Hansen & CO. grew its stake in shares of Eli Lilly and Company by 90,438.0% in the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after acquiring an additional 936,033 shares in the last quarter. GQG Partners LLC raised its holdings in shares of Eli Lilly and Company by 20.2% in the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after purchasing an additional 648,094 shares during the last quarter. Finally, Capital International Investors lifted its position in shares of Eli Lilly and Company by 8.1% during the fourth quarter. Capital International Investors now owns 6,636,833 shares of the company’s stock valued at $3,868,559,000 after purchasing an additional 497,079 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the transaction, the insider now owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 442,229 shares of company stock valued at $410,002,456. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Up 1.1 %

LLY opened at $915.04 on Friday. The company has a 50 day moving average of $895.62 and a 200 day moving average of $836.99. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The company has a market cap of $869.66 billion, a PE ratio of 134.76, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, sell-side analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LLY shares. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Finally, Truist Financial reiterated a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.